维普期刊资源整合服务平台（V6.5）

20篇 您的检索式：作者名="Kenerson"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

	题名	作者	年代	出处	被引量
1	Aberrant beta-catenin signaling in tuberous sclerosis显示文摘	Mak BC Kenerson HL Aicher LD	2005	Am J Pathol2005，167，1：	1
2	Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors 显示文摘	KENERSON H L AICHER L D TRUE L D	2002	Cancer Res2002，62，20：	1
3	Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors 显示文摘	Carroll PA Kenerson HL Yeung RS Lagunoff M	2006	J Virol2006，80，10：	1
4	The loss of tuberin promotes cell invasion through the β-catenin pathway显示文摘	Barnes EA Kenerson HL Mak BC	2010	Am J Respir Cell Mol Biol2010，43，：	1
5	Tuberin regulates E-cadherin locahzatlon: implications in epithelial-mesenchymal transition 显示文摘	Barnes EA Kenerson HL Jiang X	2010	Am J Pathol2010，177，4：	1
6	The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake 显示文摘	Jiang X Kenerson H Aicher L	2008	The American journal of pathology2008，172，6：	1
7	Effects of rapamycin in the Eker rat model of tuberous sclerosis complex显示文摘	Kenerson H Dundon TA Yeung RS	2005	Pediatr Res2005，57，1：	1
8	The tuberous sclero- sis complex regulates trafficking of glucose transporters and glucose uptake显示文摘	Jiang X Kenerson H Aieher L	2008	Am J Pathol2008，172，：	1
9	The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake 显示文摘	Jiang X Kenerson H Aicher L	2008	The American Journal of Pathology2008，172，6：	1
10	Clinical Practice Guidelines for the Management of Hypertension in the Community显示文摘	Michael A. Weber Ernesto L. Schiffrin William B. White Samuel Mann Lars H. Lindholm John G. Kenerson John M. Flack Barry L. Carter Barry J. Materson C. Venkata S. Ram Debbie L. Cohen Jean‐Claude Cadet Roger R. Jean‐Charles Sandra Taler David Kountz Raymon	2014	J Clin Hypertens2014，，1：	1
11	Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors 显示文摘	Kenerson HL Aicher LD True LD	2002	Cancer Res2002，62，20：	1
12	Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors显示文摘	Kenerson HL Aicher LD True LD	2002	Cancer Res2002，62，：	1
13	Activation of the m TOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms显示文摘	Kenerson H Folpe AL Takayama TK	2007	Hum Pathol2007，38，9：	1
14	Aberrant beta-catenin signaling in tuberous sclerosis显示文摘	Mak BC Kenerson HL Aicher LD	2005	Am J Pathol2005，167，1：	1
15	Latent Kaposi ' s sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors 显示文摘	Carroll PA Kenerson HL Yeung RS	2006	J Virol2006，80，10：	1
16	Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms显示文摘	Kenerson H Folpe AL Takayama TK	2007	Hun Pathol2007，38，9：	1
17	Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms 显示文摘	Kenerson H Folp AL Takayama TK	2007	Hum Pathol2007，38，9：	1
18	Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension显示文摘	Michael A. Weber Ernesto L. Schiffrin William B. White Samuel Mann Lars H. Lindholm John G. Kenerson John M. Flack Barry L. Carter Barry J. Materson C. Venkata S. Ram Debbie L. Cohen Jean-Claude Cadet Roger R. Jean-Charles Sandra Taler David Kountz Raymon	2014	Journal of Hypertension2014，，1：	1
19	Effects of rapamycin in the Eker rat model of tuberous sclerosis complex显示文摘	Kenerson H Dundon TA Yeung RS	2005	Pediatr Res2005，57，1：	1
20	Organotypic Models for Functional Drug Testing of Human Cancers显示文摘In the era of personalized oncology,there have been accelerated efforts to develop clinically relevant platforms to test drug sensitivities of individual cancers.An ideal assay will serve as a diagnostic companion to inform the oncologist of the various treatments that are sensitive and insensitive,thus improving outcome while minimizing unnecessary toxicities and costs.To date,no such platform exists for clinical use,but promising approaches are on the horizon that take advantage of improved techniques in creating human cancer models that encompass the entire tumor microenvironment,alongside technologies for assessing and analyzing tumor response.This review summarizes a number of current strategies that make use of intact human cancer tissues as organotypic cultures in drug sensitivity testing.	Yu Ling Huang Lindsay K.Dickerson Heidi Kenerson Xiuyun Jiang Venu Pillarisetty Qiang Tian Leroy Hood Taranjit S.Gujral Raymond S.Yeung	2023	Biomedical Engineering Frontiers2023，4，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示